[Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks? ].
D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D065095:Calcineurin Inhibitors; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007223:Infant; D055502:Secondary Prevention; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*
D000893:Anti-Inflammatory Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus
Calcineurin-Inhibitoren zur Behandlung der atopischen Dermatitis. Topische Kortikoide nur noch bei schweren Schüben?